At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 30 enrolled
Drug / intervention
Capivasertibdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Modular Phase II, Open-Label, Multicentre Study to Assess the Efficacy and Safety of Capivasertib in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (CAPITAL)
In Brief
A Phase 2 clinical trial evaluating Capivasertib for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma. Completed, enrolled 30 participants across 17 sites in 7 countries.
Detailed Summary
This study is an open-label, multicenter Phase II study of capivasertib administered orally in participants with Relapsed or Refractory (R/R) B-cell Non-Hodgkin's Lymphoma (NHL).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, Denmark, France, South Korea, Spain, United Kingdom, United States
CollaboratorsParexel
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedAug 2021
Enrollment StartNov 2021
Primary CompletionAug 2023
Study CompletionOct 2024
TodayJul 2026
First PostedAug 17, 2021
Enrollment StartNov 3, 2021
Primary CompletionAug 22, 2023
Study CompletionOct 25, 2024
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 4.9 years ago
Interventions
Capivasertibdrug
Capivasertib will be taken orally twice a day (BD) 4 days on/ 3 days off.